About
Dr Dana Shor is a Consultant in Clinical Oncology in Cambridge who specialises in the treatment of lung and upper gastrointestinal (oesophageal, gastric and small bowel) cancers and cancer of unknown primary (CUP). She provides expert, compassionate care across a full range of treatments, including systemic therapies (chemotherapy, immunotherapy and targeted therapy), conventional radiotherapy, and stereotactic ablative radiotherapy (SABR) for thoracic and upper GI malignancies.
Dr Shor completed a prestigious fellowship at the Odette Cancer Centre in Toronto, where she gained advanced expertise in SABR for lung, bone, and spine metastases, as well as stereotactic radiosurgery (SRS) for brain metastases.
In her current role at Cambridge University Hospital and Papworth Hospital, Dr Shor is part of a leading oncology team within the Department of Oncology. She serves as a principal investigator for several multicenter clinical trials, helping to advance future cancer care.
Dr Shor is committed to teaching and mentorship, having supported the British Oncology Network for Undergraduate Society. She is a trainee editor for the Clinical Oncology journal and contributes regularly to OncoFlash publications, providing updates on the latest radiotherapy research.
Clinical interests:
-All lung malignancies (early to metastasis stage)
-Malignant mesothelioma
-Upper GI malignancy (oesophageal, gastric, small bowel cancers)
-Tumours of unknown primary (CUP)
- Chemotherapy
-Immunotherapy
-Targeted therapy/molecular driver systemic therapy
-Conventional radiotherapy
-Stereotactic ablative radiotherapy (SABR) for lung, spine and bone metastases
-Radiotherapy for brain metastases and post op (PORT) brain cavity radiotherapy
-Pallitive radiotherapy
Dr Shor completed a prestigious fellowship at the Odette Cancer Centre in Toronto, where she gained advanced expertise in SABR for lung, bone, and spine metastases, as well as stereotactic radiosurgery (SRS) for brain metastases.
In her current role at Cambridge University Hospital and Papworth Hospital, Dr Shor is part of a leading oncology team within the Department of Oncology. She serves as a principal investigator for several multicenter clinical trials, helping to advance future cancer care.
Dr Shor is committed to teaching and mentorship, having supported the British Oncology Network for Undergraduate Society. She is a trainee editor for the Clinical Oncology journal and contributes regularly to OncoFlash publications, providing updates on the latest radiotherapy research.
Clinical interests:
-All lung malignancies (early to metastasis stage)
-Malignant mesothelioma
-Upper GI malignancy (oesophageal, gastric, small bowel cancers)
-Tumours of unknown primary (CUP)
- Chemotherapy
-Immunotherapy
-Targeted therapy/molecular driver systemic therapy
-Conventional radiotherapy
-Stereotactic ablative radiotherapy (SABR) for lung, spine and bone metastases
-Radiotherapy for brain metastases and post op (PORT) brain cavity radiotherapy
-Pallitive radiotherapy
“Evidence-based care tailored to each patient — taking the time to explain options and shared decisions.”
— Dr Dana Shor
Education & training
-
2006–2012 MD · Medicine and Surgery
-
2012–2016 Residency · Oncology
Career & appointments
-
2016-09–2017-08 Junior consultant
Licenses & insurance
Medical licenses
GB — Organización Médica Colegial de España (OMC)
Board certifications
European Board of Oncology
Malpractice insurance:
Allianz Professional · 4,000,000 EUR coverage · No claims on file
Procedures performed
| Procedure | Code | Lifetime count |
|---|---|---|
| GP consultation | 99213 | 2,408 |
| Annual physical exam | 99395 | 2,174 |
| Vaccination administration | 90471 | 894 |
| Minor procedure (skin) | 17110 | 825 |
Services & pricing
| Service | Duration | Modality | Price |
|---|---|---|---|
| New patient consultation (60m) | 60 min | in_clinic|telemed | 180.00 EUR |
| Follow-up consultation (30m) | 30 min | in_clinic|telemed|phone | 90.00 EUR |
| Vaccination administration | 90 min | in_clinic | 540.00 EUR |
| Minor procedure (skin) | 60 min | in_clinic | 810.00 EUR |
Office, team & in practice
Videos
Research & publications
h-index: 10 · i10: 6
-
Validation of clinical scoring in Oncology
DOI: 10.5499/euroclin.2026.0 · PMID: 36437748 · cited by 24
-
Long-term follow-up of Oncology across GB
DOI: 10.9275/euroclin.2025.1 · PMID: 31607383 · cited by 2
Invited talks
- Practical updates in Oncology European Annual Congress (Oncology) · Vienna · 2024 · invited
- Single-centre experience in Oncology National Society Meeting · Newmarket · 2023 · oral abstract
Awards & memberships
Awards
- 🏆 Top-rated Oncology — Newmarket · EuroClinics Patient Choice · 2025 · regional
- 🏆 Excellence in Patient Care · National Society · 2024 · national
Society memberships
- WONCA Europe — Family Doctors — Member · Since 2017
- national college of family doctors — Member · Since 2017
- European Union of Medical Specialists (UEMS) — Member · Since 2017
Articles by this doctor
- Patient education Patient guide to Oncology
- Awareness When should you see a oncology?
For international patients
- Coordinator
- Patient liaison · dana.shor@euroclinics.example
- Accepted international insurance
- Allianz Worldwide · AXA Global · BUPA Global · Cigna Global
Location
1 tagPatient reviews
26 verified reviews4.95
★★★★⯨
26 reviews
- Bedside Manner
- 5.0
- Knowledge
- 5.0
- Wait Time
- 4.7
- Staff Friendliness
- 5.0
- Ease Of Appointment
- 4.9
- Value For Money
- 4.9
- Would Recommend Pct
- 98.0
Share your experience — help other patients find the right doctor. Write a review →
Recent reviews
-
★★★★★ ✓ Verified Very thorough first visit — explained every step. Booking was easy and the staff were welcoming.
-
★★★★★ ✓ Verified Took time to listen and reviewed all my previous results. I would absolutely recommend.
-
★★★★☆ ✓ Verified Professional and knowledgeable. Wait on the day was a bit long, otherwise excellent.
